Himalaya Nutravedics India Limited
Bookbuilding IPO · BSE
- Price band
- ₹100 - ₹106
- Lot size
- 1,200 shares
- Issue amount
- ₹26.49 cr
- Total subscription
- 2.33×
- Opens
- 22 Sept 2026
- Closes
- 24 Sept 2026
- Allotment
- 25 Sept 2026
- Listing
- 29 Sept 2026
Offer at a glance
Issue overview
- Issue size
- 24,99,600 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,20,000
- Fresh issue
- ₹26.49 cr
- Offer for sale
- ₹0 cr
- Registrar
- Kfin Technologies Limited
- Listing exchange
- BSE
- Maximum investment
- ₹1,27,200
- Issue type
- Bookbuilding IPO
- Shares before issue
- 63,06,720
- Shares after issue
- 88,06,720
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 2 | 2,400 | ₹2,54,400 |
| sHNI | 3 | 3,600 | ₹3,81,600 |
| bHNI | 8 | 9,600 | ₹10,17,600 |
Share reservation
Subscription & GMP
Subscription by category
Reported 24 Sept 2026
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| RETAIL | 347 | 889 |
| HNIs(10L +) | 66 | 47 |
| HNIs (2-10L) | 33 | 93 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 5.02 | 5.02 |
| RETAIL | 8.83 | 22.62 |
| NIB | 3.78 | 12.9 |
| HNIs 2+ | 1.26 | 3.83 |
| HNIs 10+ | 2.52 | 9.68 |
| HNIs | 3.78 | 13.51 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Mar-26 | Mar-25 | Mar-24 |
|---|---|---|---|
| EPS | 18.33 | 24.81 | 5.13 |
| ROE | 0 | 0 | 0 |
| ROCE | 0 | 0 | 0 |
| RONW | 45.12 | 33.08 | 31.77 |
| PRE IPO(PE) | 9.04 | 0 | 0 |
| POST IPO(PE) | 12.63 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Himalaya Nutravedics India Limited | 9.04 | 0 | 10.00 | 26.70 | 45.12 | 12.05 |
| Jeena Sikho Lifecare Limited | 28.75 | 0 | 2.00 | 37.60 | 27.67 | 17.84 |
| Sandu Pharmaceuti cals Limite | 20.62 | 0 | 10.00 | 45.21 | 2.53 | 1.83 |
Company information
Company profile
Himalaya Nutravedics India Ltd is engaged in the manufacturing, marketing, and distribution of Ayurvedic and nutraceutical formulations in India, along with offering third-party contract manufacturing services for other companies in this space. The company has a diversified product portfolio comprising classical Ayurvedic formulations based on traditional texts, proprietary Ayurvedic products, and nutraceutical supplements, available in various dosage forms such as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals, and medicated oils. It operates on a hybrid business model that balances its own branded products with contract manufacturing, supported by an integrated in-house manufacturing facility located in Hyderabad, Telangana. As of September 2025, its products are distributed across multiple states including Telangana, Andhra Pradesh, Kerala, Gujarat, and Uttar Pradesh, with offerings catering to a wide range of wellness segments such as digestive health, immunity, metabolic health, joint care, reproductive health, respiratory wellness, pain management, and overall well-being, aligned with regulatory standards.
Strengths
- Integrated Multi-Dosage Manufacturing: The company can manufacture different dosage forms, including capsules, tablets, oils, liquid orals and powders. This enables it to serve varied product needs across multiple therapeutic categories.
- Strong Doctor Acceptance: The company promotes its branded products through healthcare practitioners, with product acceptance driven by performance rather than mass advertising. This supports its established branded product portfolio.
- Long-Standing Relationships: Himalaya Nutravedics has built lasting relationships with its suppliers and customers. These relationships help support smooth procurement and sales operations.
Risk factors
- Dependence on Ayurvedic Products: Ayurvedic products contributed 94.57%, 92.09% and 79.27% of revenue from operations in Fiscal 2026, 2025 and 2024, respectively. A decline in demand for these products could negatively affect the company’s business and financial performance.
- Customer Concentration: The top 10 customers contributed 81.24%, 86.97% and 84.19% of revenue from operations in Fiscal 2026, 2025 and 2024, respectively. Losing key customers or facing lower or delayed orders could impact revenue, financial condition and cash flows.
- Supplier Concentration: The company has historically sourced a significant share of its requirements from its top 10 suppliers. Any disruption in these supplier relationships could affect the availability of raw materials and other essential supplies.
Promoters
Rohit Asawa
Divya Asawa
Chanda Asawa
Rama Raju
Registrar & documents
Lead manager
Nirbhay Capital Services Private Limited
Registrar & contacts
Kfin Technologies Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
Plot No. 101/A, Phase-III, Industrial Development Park, Cherlapally, Hindustan Cables Ltd, Uppal Hyderabad, Telangana, 500051
+91-9063498493
[email protected]Company website ↗Understanding HNIL IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.